Tritanium® Primary Acetabular Shell Study
Terminated · Not applicable · NCT01063751
Conditions: Arthroplasty, Replacement, Hip
At a glance
- Research payments reported, 2025
- $2,880
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 275
About the trial
- Sponsor
- Stryker Orthopaedics
- Tested
- Tritanium® Primary Acetabular Shell (device)
- Dates
- Started 2011-07; completion 2023-12-30
- Results posted
- Yes
This study will be a prospective, non-randomized evaluation of the Tritanium® Acetabular Shell for primary total hip replacement (THR) with a cementless application in a consecutive series of patients who meet the eligibility criteria. Half of the cases will use the Trident® X3® polyethylene insert alone as the bearing surface; the other half will use the modular dual mobility (MDM™) liner coupled with a compatible anatomic dual mobility (ADM™)/MDM™ X3® insert as the bearing surface. The success rate, defined as freedom from acetabular revision for any reason, for hips implanted with the Tritanium® Acetabular Shell, is no worse than for hips implanted with similar technology as reported i…
From ClinicalTrials.gov, last updated 2025-04-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Stryker Corporation reported $2,880 in research payments for this study in 2025 (1 payments).
Products named: Tritanium
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of North Carolina at Chapel Hill $2,880
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.